edaravone + rosuvastatin + sildenafil

This is an **experimental combination of three small-molecule drugs: edaravone, rosuvastatin, and sildenafil**, each with independent pharmacological actions and approved uses. There is no uniquely approved product or fixed-dose combination marketed under this combination; studies have evaluated their **concurrent administration primarily to assess pharmacokinetics and drug-drug interactions** in healthy volunteers. - **Edaravone** is a free radical scavenger indicated for the treatment of amyotrophic lateral sclerosis (ALS)[3][5]. - **Rosuvastatin** is a potent HMG-CoA reductase inhibitor (statin) used to lower lipid levels and reduce cardiovascular risk[6]. - **Sildenafil** is a phosphodiesterase-5 inhibitor (PDE5 inhibitor) approved for treating erectile dysfunction and pulmonary arterial hypertension[4]. The combination was studied to investigate possible pharmacokinetic and metabolic interactions due to the involvement of transporter proteins and cytochrome P450 pathways, but **no notable interactions or adverse pharmacokinetic effects were observed**[1][3]. This combination is not known to be in clinical development as a fixed multi-component therapeutic for any specific disease.